文献速递细菌感染、耐药与抗菌药物医院感染防控

新型抗生素经济学评价:去定植减少医疗传播的高潜在价值

Economic Evaluations of New Antibiotics: The High Potential Value of Reducing Healthcare Transmission Through Decolonization.
PubMed 文献 · Clin Infect Dis · 2021-01-01

研究建立数学传播模型,模拟两种针对长期急性护理医院住院患者中碳青霉烯耐药肠杆菌(CRE)的假设抗生素:一种降低CRE血流感染(BSI)患者死亡率,另一种在临床检出后对CRE携带者去定植。比较直接效应与直接加间接效应后,去定植抗生素在多数场景下成为优势策略(成本更低且效果更好)。

要点

  • 去定植抗生素考虑间接传播效应后,相对常规护理和BSI治疗抗生素均提高相对效果并降低相对成本。
  • 多数场景下去定植药物为优势策略,即成本更低且更有效。
  • 对受疫情威胁人群,去定植抗生素的间接效益可显著提升成本效果。

核心结论

  • 当考虑对疫情脆弱人群的间接效益时,去定植耐药菌携带者的抗生素可具有高度成本效果。

研究设计与样本

  • 研究建立数学传播模型,量化两种假设抗生素对长期急性护理医院住院患者中CRE的影响。
  • 一种假设抗生素降低CRE血流感染患者死亡率,另一种假设在临床检出后对CRE携带者去定植。
  • 将结果应用于成本效果分析,效果结局为获得生命年,并假设抗生素剂量和CRE BSI的成本。

主要发现

  • 去定植抗生素纳入间接效应后,相对常规护理和BSI治疗抗生素均提高相对效果并降低相对成本。
  • 多数场景下去定植药物为优势策略,即成本更低且更有效。

临床怎么用

  • 评估去定植抗生素时应纳入对人群传播的间接效益,而非仅看受者直接获益。
  • 在美国,对受者直接获益不明确的药物难以获得FDA批准和开发者财务回报,需探索激励去定植抗生素开发的途径。

局限性

  • 研究基于假设抗生素和模型假设,结论需实际数据验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antibiotics designed to decolonize carriers of drug-resistant organisms could offer substantial population health benefits, particularly if they can help avert outbreaks by interrupting person-to-person transmission chains. However, cost effectiveness of an antibiotic is typically evaluated only according to its benefits to recipients, which can be difficult to demonstrate for carriers of an organism that may not pose an immediate health threat to the carrier. METHODS: We developed a mathematical transmission model to quantify the effects of 2 hypothetical antibiotics targeting carbapenem-resistant Enterobacteriaceae (CRE) among long-term acute care hospital inpatients: one assumed to decrease the death rate of patients with CRE bloodstream infections (BSIs) and the other assumed to decolonize CRE carriers after clinical detection. We quantified the effect of each antibiotic on the number of BSIs and deaths among patients receiving the drug (direct effect) and among all patients (direct and indirect effect) compared to usual care. We applied these results to a cost-effectiveness analysis with effectiveness outcome of life-years gained and assumed costs for antibiotic doses and for CRE BSI. RESULTS: The decolonizing antibiotic, once indirect effects were included, produced increased relative effectiveness and decreased relative costs compared to both usual care and the BSI treatment antibiotic. In fact, in most scenarios, the decolonizing drug was the dominant treatment strategy (ie, less costly and more effective). CONCLUSIONS: Antibiotics that decolonize carriers of drug-resistant organisms can be highly cost-effective when considering indirect benefits within populations vulnerable to outbreaks. Public health could benefit from finding ways to incentivize development of decolonizing antibiotics in the US, where drugs with unclear direct benefits to recipients would pose difficulties in achieving FDA approval and financial benefit to the developer.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Toth DJA, Samore MH, Nelson RE, et al. Economic Evaluations of New Antibiotics: The High Potential Value of Reducing Healthcare Transmission Through Decolonization. Clin Infect Dis. 2021. PMID: 33512525. doi:10.1093/cid/ciaa1590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。